Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy.
Humans
Antibodies, Monoclonal, Murine-Derived
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Basic Helix-Loop-Helix Transcription Factors
/ genetics
Cyclophosphamide
/ therapeutic use
Doxorubicin
/ therapeutic use
Lymphoma, Large B-Cell, Diffuse
/ diagnosis
Prednisone
/ therapeutic use
Prognosis
Rituximab
/ therapeutic use
Up-Regulation
Vincristine
/ therapeutic use
Diffuse large B-cell lymphoma
biomarkers
gene expression
machine learning
oncogenes
prognosis
survival
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
pubmed:
8
11
2022
medline:
9
2
2023
entrez:
7
11
2022
Statut:
ppublish
Résumé
TCF3 is a lymphopoietic transcription factor that acquires somatic driver mutations in diffuse large B-cell lymphoma (DLBCL). Hypothesizing that expression patterns of TCF3-regulated genes can inform clinical management, we found that unsupervised clustering analysis with 15 TCF3-regulated genes and eight additional ones resolved local DLBCL cases into two main clusters, denoted Groups A and B, of which Group A manifested inferior overall survival (OS,
Identifiants
pubmed: 36336953
doi: 10.1080/10428194.2022.2136968
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Basic Helix-Loop-Helix Transcription Factors
0
Cyclophosphamide
8N3DW7272P
Doxorubicin
80168379AG
Prednisone
VB0R961HZT
Rituximab
4F4X42SYQ6
TCF3 protein, human
0
Vincristine
5J49Q6B70F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM